Danish pharmaceutical giant Novo Nordisk has reported exceptional third-quarter results, driven by remarkable sales of its weight-loss treatment Wegovy. The anti-obesity medication generated sales of 17.3 billion Danish krone (£1.96
Danish pharmaceutical giant Novo Nordisk has reported exceptional third-quarter results, driven by remarkable sales of its weight-loss treatment Wegovy. The anti-obesity medication generated sales of 17.3 billion Danish krone (£1.96






